Stifel analyst Paul Matteis upgraded Acadia Pharmaceuticals (ACAD) to a Buy from a Hold today and raised his target price to $71 from $41. (Shares closed at $57 today, up 6.17%) The upgrade from Matteis was especially powerful since he has been skeptical on the stock and the potential for its primavanserin to win approval for […]
To subscribe to JAM you need to fill in some details below including, ahem, some info on how you'll pay us. A subscription is $199 (although if you're subscribing with one of our special offers it will be lower) for a year for ongoing and continuing access to the site. And we'll throw in the first week free! If you change your mind during that first week, just cancel your subscription from your profile page, and you won't be billed anything.
